CoChat
Sign Up
Cited by 318Epilepsy research and treatmentNeuroscience and Neuropharmacology ResearchPharmacological Effects and Toxicity Studies

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.

Antiepileptic Drugs in Non-Epilepsy Disorders: Relations between Mechanisms of Action and Clinical Efficacy

Johannessen Landmark, Cecilie·2008·CNS Drugs
DOI 10.2165/00023210-200822010-00003
Open this paper in CoChat — free account

Abstract

Antiepileptic drugs (AEDs) are used extensively to treat multiple non-epilepsy disorders, both in neurology and psychiatry. This article provides a review of the clinical efficacy of AEDs in non-epilepsy disorders based on recently published preclinical and clinical studies, and attempts to relate this efficacy to the mechanism of action of AEDs and pathophysiological processes associated with the disorders. Some newer indications for AEDs have been established, while others are under investigation. The disorders where AEDs have been demonstrated to be of clinical importance include neurological disorders, such as essential tremor, neuropathic pain and migraine, and psychiatric disorders, including anxiety, schizophrenia and bipolar disorder. Many of the AEDs have various targets of action in the synapse and have several proposed relevant mechanisms of action in epilepsy and in other disorders. Pathophysiological processes disturb neuronal excitability by modulating ion channels, receptors and intracellular signalling pathways, and these are targets for the pharmacological action of various AEDs. Attention is focused on the glutamatergic and GABAergic synapses. In psychiatric conditions such as schizophrenia and bipolar disorder, AEDs such as valproate, carbamazepine and lamotrigine appear to have clear roles based on their effect on intracellular pathways. On the other hand, some AEDs, e.g. topiramate, have efficacy for nonpsychiatric disorders including migraine, possibly by enhancing GABAergic and reducing glutamatergic neurotransmission. AEDs that seem to enhance GABAergic neurotransmission, e.g. tiagabine, valproate, gabapentin and possibly levetiracetam, may have a role in treating neurological disorders such as essential tremor, or anxiety disorders. AEDs with effects on voltage-gated sodium or calcium channels may be advantageous in treating neuropathic pain, e.g. gabapentin, pregabalin, carbamazepine, oxcarbazepine, lamotrigine and valproate. Co-morbid conditions associated with epilepsy, such as mood disorders and migraine, may often respond to treatment with AEDs. Other possible disorders where AEDs may be of clinical importance include cancer, HIV infection, drug and alcohol abuse, and also in neuroprotection. A future challenge is to evaluate the second-generation AEDs in non-epilepsy disorders and to design clinical trials to study their effects in such disorders in paediatric patients. Differentiation between the main mechanisms of action of the AEDs needs more consideration in drug selection for tailored treatment of the various non-epilepsy disorders.

Overview

Integrity signals

Registry

Crossref · 10.2165/00023210-200822010-00003

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 157 references

Research works printed but not linked: 14

  1. Lydiard, 2003, J Clin Psychiatry, 64, 21
  2. Nemeroff, 2003, Psychopharmacol Bull, 37, 133
  3. Kralic, 2005, J Clin Invest, 115, 584, 10.1172/JCI200523625 · DOI
  4. Chetcuti, 2005, Int J Neuropsychopharmacol, 28, 1
  5. Keck, 2005, JClin Psychiatry, 67, 8
  6. Premkumar, 2006, Cochrane Database Syst Rev, &NA;, CD005962
  7. Drake, 2001, Cephalalgia, 21, 373
  8. Krusz, 2001, Cephalalgia, 21, 373
  9. Keck, 1993, J Clin Psychiatry, 54, 305
  10. Manji, 2001, Psychopharmacol Bull, 35, 5
  11. Owens, 2003, Psychopharmacol Bull, 37, 17
  12. Henry, 2003, Psychopharmacol Bull, 37, 5
  13. Myrick, 2003, Prim Psychiatry, 10, 59
  14. De Paulis, 2003, Curr Opin Invest Drug, 4, 863

Cited by

Sorted by citations

Items 201–300 of 318

Related

See all

Metadata

Authors
Johannessen Landmark, C.
Venue
CNS Drugs
Publisher
Springer Science and Business Media LLC
Published
2008
Volume
22
Issue
1
Pages
27-47
ISSN
1172-7047 (ISSN-L)
DOI
10.2165/00023210-200822010-00003
OpenAlex
W2195324906
Cited by
316
References
157
Citations by year
2026: 5 · 2025: 4 · 2024: 11 · 2023: 15 · 2022: 9 · 2021: 7 · 2020: 5 · 2019: 17 · 2018: 10 · 2017: 10 · 2016: 22 · 2015: 15 · 2014: 18 · 2013: 27 · 2012: 28
FWCI
4.86
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords
antiepileptic drugs, off-label drug use, essential tremor, neuropathic pain, migraine, anxiety disorders, schizophrenia, bipolar disorder, GABAergic neurotransmission, glutamatergic neurotransmission, ion channels, valproic acid, carbamazepine, lamotrigine, topiramate, gabapentin, pregabalin, tiagabine, mood disorders, neuroprotection, second-generation antiepileptic drugs, drug selection
MeSH terms
Anticonvulsants, Anxiety, Mental Disorders, Bipolar Disorder, Humans, Migraine Disorders, Nervous System Diseases, Pain, Schizophrenia, Essential Tremor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review